Vira-Shield

Información principal

  • Denominación comercial:
  • Vira-Shield D6 + VL. Swissagro.
  • Unidades en paquete:
  • 250 ml (50ds)
  • Usar para:
  • Animales
  • Tipo de medicina:
  • medicamento alopático

Documentos

  • para el público en general:
  • El prospecto de información de este producto no está disponible actualmente, puede enviar una petición a nuestro servicio al cliente y le notificaremos tan pronto como nos sea posible para conseguirlo.


    Solicitar el prospecto de información al público.

Localización

  • Disponible en:
  • Vira-Shield D6 + VL. Swissagro.
    Venezuela
  • Idioma:
  • español

Información terapéutica

  • indicaciones terapéuticas:
  • Para vacunar animales sanos en la prevención de las enfermedades causadas por Virus de la Rinotraqueitis bovina, virus de la diarrea tipo 1 y tipo 2, parainfluenza tipo 3 y virus respiratorio sincicial, leptospiras canícola, grippottyphosa, hardjo, icterrohemorragiae y Pomona.
  • Resumen del producto:
  • Administrar 5ml vía intramuscular , repitiendo la dosis a las 4 – 5 semanas. Revacunar cada año.

Otros datos

Estado

  • Fuente:
  • Instituto Nacional de Higiene - República Bolivariana de Venezuela
  • última actualización:
  • 03-09-2018
  • El prospecto de información de este producto no está disponible actualmente, puede enviar una petición a nuestro servicio al cliente y le notificaremos tan pronto como nos sea posible para conseguirlo.

    Solicitar el prospecto de información al público.

30-10-2018

Meningitis aséptica inducida por fármacos

Boletín de Farmacovigilancia de Cataluña Vol. 16, n.º 4 • julio - septiembre 2018 La meningitis aséptica inducida por fármacos (MAIF) se caracteriza por los resultados negativos de todos los cultivos microbiológicos y serologías, incluidos bacterias, virus y hongos. Es, por tanto, un diagnóstico de exclusión y sigue una relación temporal compatible con el inicio de exposición al fármaco sospechoso. Pueden causarla AINE, antibióticos, antifúngicos, antivirales, antiparasitarios, inmunosupresores, i...

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

16-10-2018

Assessment of low pathogenic avian influenza virus transmission via raw poultry meat and raw table eggs

Assessment of low pathogenic avian influenza virus transmission via raw poultry meat and raw table eggs

Published on: Mon, 15 Oct 2018 00:00:00 +0200 A rapid qualitative assessment has been done by performing a theoretical analysis on the transmission of low pathogenic avian influenza (LPAI) via fresh meat from poultry reared or kept in captivity for the production of meat (raw poultry meat) or raw table eggs. A predetermined transmission pathway followed a number of steps from a commercial or non‐commercial poultry establishment within the EU exposed to LPAI virus (LPAIV) to the onward virus transmission...

Europe - EFSA - European Food Safety Authority Publications

10-10-2018

Prescripción de antibióticos asociados a faringoamigdalitis en menores de 14 años

Ojo de Markov número setenta y seis - septiembre 2018 Sacyl 28 de septiembre de 2018 La mayoría de las faringoamigdalitis son de origen vírico (70-85%) y ocurren en el contexto de un cuadro catarral acompañadas de síntomas virales como congestión nasal, febrícula, tos, disfonía, conjuntivitis, cefalea o mialgia, evolucionando normalmente de manera favorable con tratamiento sintomático.Los antibióticos sólo son eficaces en las faringitis de causa bacteriana, cuya etiología más frecuente es el estre...

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

4-6-2018

Un nuevo mecanismo molecular explica la persistencia del VIH

Un nuevo mecanismo molecular explica la persistencia del VIH

Investigadores del Hospital Brigham & Women´s han descubierto que la inducción de la proteína antiapoptótica BIRC5 es esencial en la supervivencia de los linfocitos T CD4+ infectados por el VIH-1. Mediante el uso de una sofisticada técnica de proteómica basada en la espectrometría de masas cuantitativa, los científicos han determinado que la infección viral activa […]

Cuba - infomed - Red de Salud de Cuba

2-6-2018

El virus del Zika elimina tumores humanos avanzados en el sistema nervioso central

El virus del Zika elimina tumores humanos avanzados en el sistema nervioso central

La actividad viral quedó demostrada en un estudio con ratones. Un grupo de científicos brasileños pretende patentar un kit farmacéutico y avanzar hacia la fase de ensayos clínicos. En el marco de un estudio realizado en Brasil y publicado el pasado mes de abril en la CancerResearch quedó demostrado por primera vez In vivo que […]

Cuba - infomed - Red de Salud de Cuba

26-5-2018

Shadow Holdings, LLC Issues Voluntary Nationwide Recall of X-Jow and Acne Shave products due to Possible Bacterial Contamination

Shadow Holdings, LLC Issues Voluntary Nationwide Recall of X-Jow and Acne Shave products due to Possible Bacterial Contamination

Shadow Holdings is voluntarily recalling all lots, within expiry, of Herb-X Solutions X-Jow Pain Gel, and United Exchange Acne Shave Moisturizer, Acne Shave Shave Cream with Acne Shield, and Acne Shave Shave Kit to the retail level. The products may be contaminated with bacteria.

FDA - U.S. Food and Drug Administration

30-10-2018

EU/3/18/2080 (Freeline Therapeutics Ltd)

EU/3/18/2080 (Freeline Therapeutics Ltd)

EU/3/18/2080 (Active substance: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant) - Orphan designation - Commission Decision (2018)7281 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/127/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2079 (Spark Therapeutics Ireland Ltd)

EU/3/18/2079 (Spark Therapeutics Ireland Ltd)

EU/3/18/2079 (Active substance: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII) - Orphan designation - Commission Decision (2018)7280 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/104/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2073 (Fondazione Telethon)

EU/3/18/2073 (Fondazione Telethon)

EU/3/18/2073 (Active substance: Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA) - Orphan designation - Commission Decision (2018)7274 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/113/18

Europe -DG Health and Food Safety

2-10-2018

EU/3/16/1786 (Voisin Consulting S.A.R.L.)

EU/3/16/1786 (Voisin Consulting S.A.R.L.)

EU/3/16/1786 (Active substance: Recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein) - Transfer of orphan designation - Commission Decision (2018)6427 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/183/16/T/02

Europe -DG Health and Food Safety

2-10-2018

ViraferonPeg (Merck Sharp and Dohme B.V.)

ViraferonPeg (Merck Sharp and Dohme B.V.)

ViraferonPeg (Active substance: Peginterferon alfa-2b) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6477 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/329/T/128

Europe -DG Health and Food Safety

28-8-2018

EU/3/18/2060 (Biogen Idec Limited)

EU/3/18/2060 (Biogen Idec Limited)

EU/3/18/2060 (Active substance: Adeno-associated viral vector serotype hu68 containing the human SMN1 gene) - Orphan designation - Commission Decision (2018)5732 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/065/18

Europe -DG Health and Food Safety

27-8-2018

Strimvelis (Orchard Therapeutics (Netherlands) B.V.)

Strimvelis (Orchard Therapeutics (Netherlands) B.V.)

Strimvelis (Active substance: autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5703 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3854/T/14

Europe -DG Health and Food Safety

7-8-2018

EU/3/16/1694 (GlaxoSmithKline Trading Services Limited)

EU/3/16/1694 (GlaxoSmithKline Trading Services Limited)

EU/3/16/1694 (Active substance: Autologous CD4+ and CD8+ T-cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1) - Transfer of orphan designation - Commission Decision (2018)5405 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/064/16/T/01

Europe -DG Health and Food Safety

3-8-2018

EU/3/18/2042 (MeiraGTx UK II Limited)

EU/3/18/2042 (MeiraGTx UK II Limited)

EU/3/18/2042 (Active substance: Adenovirus associated viral vector serotype 2/8 containing the human CNGA3 gene) - Orphan designation - Commission Decision (2018)5274 of Fri, 03 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/048/18

Europe -DG Health and Food Safety

2-8-2018

EU/3/16/1660 (Orchard Therapeutics Ltd)

EU/3/16/1660 (Orchard Therapeutics Ltd)

EU/3/16/1660 (Active substance: Autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene) - Transfer of orphan designation - Commission Decision (2018)5288 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/024/16/T/02

Europe -DG Health and Food Safety

2-8-2018

EU/3/07/446 (Orchard Therapeutics Ltd)

EU/3/07/446 (Orchard Therapeutics Ltd)

EU/3/07/446 (Active substance: Autologous CD34+ cells transfected with lentiviral vector containing the human arylsulfatase A cDNA) - Transfer of orphan designation - Commission Decision (2018)5287 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/102/06/T/02

Europe -DG Health and Food Safety

1-8-2018

Strimvelis (GlaxoSmithKline Trading Services Limited)

Strimvelis (GlaxoSmithKline Trading Services Limited)

Strimvelis (Active substance: autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) - Centralised - Yearly update - Commission Decision (2018)5217 of Wed, 01 Aug 2018

Europe -DG Health and Food Safety

30-7-2018

Zalmoxis (MolMed S.p.A.)

Zalmoxis (MolMed S.p.A.)

Zalmoxis (Active substance: Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (?LNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) - Centralised - Renewal - Commission Decision (2018)5118 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2801/R/10

Europe -DG Health and Food Safety

27-7-2018

EU/3/14/1263 (bluebird bio (Germany) GmbH)

EU/3/14/1263 (bluebird bio (Germany) GmbH)

EU/3/14/1263 (Active substance: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) - Transfer of orphan designation - Commission Decision (2018)5035 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/184/13/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/12/1091 (bluebird bio (Germany) GmbH)

EU/3/12/1091 (bluebird bio (Germany) GmbH)

EU/3/12/1091 (Active substance: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene) - Transfer of orphan designation - Commission Decision (2018)5032 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/146/12/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/12/1003 (bluebird bio (Germany) GmbH)

EU/3/12/1003 (bluebird bio (Germany) GmbH)

EU/3/12/1003 (Active substance: Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA) - Transfer of orphan designation - Commission Decision (2018)5033 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/009/12/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/12/998 (Orchard Therapeutics Ltd)

EU/3/12/998 (Orchard Therapeutics Ltd)

EU/3/12/998 (Active substance: Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene) - Transfer of orphan designation - Commission Decision (2018)5062 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/014/12/T/02

Europe -DG Health and Food Safety

29-6-2018

EU/3/18/2039 (REGENXBIO EU Limited)

EU/3/18/2039 (REGENXBIO EU Limited)

EU/3/18/2039 (Active substance: Recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene) - Orphan designation - Commission Decision (2018)4184 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/027/18

Europe -DG Health and Food Safety

27-6-2018

EU/3/17/1874 (Sangamo Therapeutics UK LTD)

EU/3/17/1874 (Sangamo Therapeutics UK LTD)

EU/3/17/1874 (Active substance: Recombinant adeno-associated viral vector serotype 6 encoding the B-domain-deleted human factor VIII) - Transfer of orphan designation - Commission Decision (2018)4099 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/019/17/T/01

Europe -DG Health and Food Safety

19-6-2018

Invirase (Roche Registration GmbH)

Invirase (Roche Registration GmbH)

Invirase (Active substance: Saquinavir) - Corrigendum - Commission Decision (2018)1950 of Tue, 19 Jun 2018

Europe -DG Health and Food Safety

12-6-2018

EU/3/17/1956 (Sangamo Therapeutics UK LTD)

EU/3/17/1956 (Sangamo Therapeutics UK LTD)

EU/3/17/1956 (Active substance: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene) - Transfer of orphan designation - Commission Decision (2018)3811 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/168/17/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/17/1955 (Sangamo Therapeutics UK LTD)

EU/3/17/1955 (Sangamo Therapeutics UK LTD)

EU/3/17/1955 (Active substance: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene) - Transfer of orphan designation - Commission Decision (2018)3810 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/167/17/T/01

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2016 (Abeona Therapeutics Europe SL)

EU/3/18/2016 (Abeona Therapeutics Europe SL)

EU/3/18/2016 (Active substance: Adeno-associated viral vector serotype 9 containing the human CLN1 gene) - Orphan designation - Commission Decision (2018)3383 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/013/18

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2015 (Baxalta Innovations GmbH)

EU/3/18/2015 (Baxalta Innovations GmbH)

EU/3/18/2015 (Active substance: Adeno-associated viral vector serotype 8 containing a functional copy of the codon-optimised F8 cDNA encoding the B-domain deleted human coagulation factor VIII) - Orphan designation - Commission Decision (2018)3382 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/18

Europe -DG Health and Food Safety

18-5-2018

EU/3/16/1745 (Novartis Europharm Limited)

EU/3/16/1745 (Novartis Europharm Limited)

EU/3/16/1745 (Active substance: Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19) - Transfer of orphan designation - Commission Decision (2018)3146 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/087/16/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1266 (Novartis Europharm Limited)

EU/3/14/1266 (Novartis Europharm Limited)

EU/3/14/1266 (Active substance: Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19) - Transfer of orphan designation - Commission Decision (2018)3145 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/187/13/T/01

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2008 (StolmAr and Partner PatentanwAlte PartG mbB)

EU/3/18/2008 (StolmAr and Partner PatentanwAlte PartG mbB)

EU/3/18/2008 (Active substance: Adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1) - Orphan designation - Commission Decision (2018)2404 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/254/17

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2007 (Dr Philippe Moullier)

EU/3/18/2007 (Dr Philippe Moullier)

EU/3/18/2007 (Active substance: Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene) - Orphan designation - Commission Decision (2018)2403 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/255/17

Europe -DG Health and Food Safety